MXPA04002652A - Composiciones de disgregacion intraoral organolepticamente aceptables. - Google Patents

Composiciones de disgregacion intraoral organolepticamente aceptables.

Info

Publication number
MXPA04002652A
MXPA04002652A MXPA04002652A MXPA04002652A MXPA04002652A MX PA04002652 A MXPA04002652 A MX PA04002652A MX PA04002652 A MXPA04002652 A MX PA04002652A MX PA04002652 A MXPA04002652 A MX PA04002652A MX PA04002652 A MXPA04002652 A MX PA04002652A
Authority
MX
Mexico
Prior art keywords
organoleptically acceptable
disintegrating compositions
intraorally disintegrating
compositions
intraorally
Prior art date
Application number
MXPA04002652A
Other languages
English (en)
Inventor
P Reo Joseph
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MXPA04002652A publication Critical patent/MXPA04002652A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan tabletas de disolucion rapida que se desintegran oralmente y procesos para preparar dichas formas de dosis. Las composiciones son utiles en el tratamiento o profilaxis de muchas condiciones y enfermedades.
MXPA04002652A 2001-09-26 2002-09-23 Composiciones de disgregacion intraoral organolepticamente aceptables. MXPA04002652A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32535601P 2001-09-26 2001-09-26
PCT/US2002/030048 WO2003026697A2 (en) 2001-09-26 2002-09-23 Organoleptically acceptable intraorally disintegrating compositions

Publications (1)

Publication Number Publication Date
MXPA04002652A true MXPA04002652A (es) 2004-06-07

Family

ID=23267542

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA04002652A MXPA04002652A (es) 2001-09-26 2002-09-23 Composiciones de disgregacion intraoral organolepticamente aceptables.
MXPA04002798A MXPA04002798A (es) 2001-09-26 2002-09-23 Composiciones de valdecoxib de disgregacion intraoral.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MXPA04002798A MXPA04002798A (es) 2001-09-26 2002-09-23 Composiciones de valdecoxib de disgregacion intraoral.

Country Status (25)

Country Link
US (1) US20030181501A1 (es)
EP (2) EP1429736A2 (es)
JP (2) JP2005512964A (es)
KR (2) KR20040058189A (es)
CN (2) CN1633281A (es)
AP (2) AP2004002999A0 (es)
AR (1) AR037239A1 (es)
BR (2) BR0212778A (es)
CA (2) CA2461630A1 (es)
CO (2) CO5570684A2 (es)
EA (2) EA200400357A1 (es)
EC (1) ECSP045029A (es)
GE (1) GEP20063856B (es)
HK (1) HK1079988A1 (es)
IL (2) IL160848A0 (es)
IS (2) IS7177A (es)
MA (2) MA27542A1 (es)
MX (2) MXPA04002652A (es)
NO (2) NO20041258L (es)
OA (2) OA12707A (es)
PL (2) PL369297A1 (es)
TN (2) TNSN04045A1 (es)
WO (2) WO2003026697A2 (es)
YU (1) YU34804A (es)
ZA (2) ZA200401953B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002557A1 (en) * 2003-07-03 2005-01-13 Warner-Lambert Company Llc Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
US20050186271A1 (en) * 2004-02-24 2005-08-25 Sheskey Paul J. Process for dispersing a fluid in a mass of solid particles
JP5551852B2 (ja) * 2004-08-10 2014-07-16 味の素株式会社 苦味の低減したナテグリニド含有製剤
JP5209876B2 (ja) * 2004-12-28 2013-06-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 速崩壊性錠剤及びその製造方法
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
KR20080080318A (ko) * 2005-12-20 2008-09-03 에자이 알앤드디 매니지먼트 가부시키가이샤 지용성 약물을 함유하는 구강내 속붕정
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
WO2007087188A2 (en) * 2006-01-20 2007-08-02 Merck & Co., Inc. Taste-masked tablets and granules
US20070196494A1 (en) * 2006-02-17 2007-08-23 Arnaud Grenier Low-friability, patient-friendly orally disintegrating formulations
CA2687124A1 (en) * 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia
WO2008148731A1 (de) * 2007-06-06 2008-12-11 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
US20100184785A1 (en) * 2007-06-06 2010-07-22 Basf Se Pharmaceutical formulation for the production of chewable tablets and lozenges
KR20100033400A (ko) * 2007-06-06 2010-03-29 바스프 에스이 급속 붕해 정제의 제조를 위한 제약 제제
KR20160083132A (ko) * 2007-06-06 2016-07-11 바스프 에스이 급속 붕해 정제의 제조를 위한 제약 제제
KR101606944B1 (ko) * 2007-08-07 2016-03-28 아셀알엑스 파마슈티컬스 인코퍼레이티드 경구 경점막 투여형을 사용한 시술시 진정과 무통을 위한 조성물 및 방법
EP2268268A2 (en) * 2008-03-24 2011-01-05 Wockhardt Research Centre Orally disintegrating compositions of rhein or diacerein
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
KR101753411B1 (ko) * 2008-11-25 2017-07-03 미쓰비시 타나베 파마 코퍼레이션 구강 내 속붕괴성정 및 그의 제조 방법
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
FR2968995B1 (fr) * 2010-12-16 2013-03-22 Sanofi Aventis Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage
CN106822007B (zh) 2015-09-11 2021-12-31 西姆莱斯股份公司 口服制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
PE10898A1 (es) * 1995-06-13 1998-03-20 American Home Prod Formulaciones orales de etodolac s (+)-
US5954204A (en) * 1995-10-20 1999-09-21 Phatmacia & Upjohn Company Blister package
HUP9902889A3 (en) * 1996-05-17 2002-04-29 Merck Frosst Canada & Co Kirkl The use of 3-phenyl-4-(4-methylsulphonyl)-phenyl-2-(5h)-furanone for producing anti inflammatory medicaments and such medicaments
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
CA2362816C (en) * 1999-12-08 2007-02-06 Pharmacia Corporation Valdecoxib compositions
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6800297B2 (en) * 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
ATE329583T1 (de) * 2000-08-18 2006-07-15 Pharmacia Corp Schnell zerfallende orale arzneizubereitung enthaltend valdecoxib
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物

Also Published As

Publication number Publication date
EP1490035A1 (en) 2004-12-29
WO2003026697A2 (en) 2003-04-03
CO5570659A2 (es) 2005-10-31
ZA200402364B (en) 2005-01-13
OA13060A (en) 2006-11-10
MXPA04002798A (es) 2004-07-05
CO5570684A2 (es) 2005-10-31
KR20040044990A (ko) 2004-05-31
IS7178A (is) 2004-03-11
OA12707A (en) 2006-06-26
GEP20063856B (en) 2006-06-26
PL369298A1 (en) 2005-04-18
TNSN04045A1 (fr) 2006-06-01
NO20041258L (no) 2003-03-27
CN1703203A (zh) 2005-11-30
NO20041532L (no) 2004-04-15
IS7177A (is) 2004-03-11
EP1429736A2 (en) 2004-06-23
JP2005512964A (ja) 2005-05-12
AP2004002999A0 (en) 2004-03-31
JP2005506987A (ja) 2005-03-10
IL160848A0 (en) 2004-08-31
MA27542A1 (fr) 2005-10-03
WO2003026623A1 (en) 2003-04-03
TNSN04047A1 (fr) 2006-06-01
ZA200401953B (en) 2005-05-09
WO2003026697A3 (en) 2003-07-03
WO2003026623A8 (en) 2004-09-30
EA200400352A1 (ru) 2004-12-30
EA200400357A1 (ru) 2004-08-26
AP2004002998A0 (en) 2004-03-31
AR037239A1 (es) 2004-11-03
CN1633281A (zh) 2005-06-29
KR20040058189A (ko) 2004-07-03
IL160855A0 (en) 2004-08-31
HK1079988A1 (zh) 2006-04-21
BR0212778A (pt) 2004-12-07
YU34804A (sh) 2006-08-17
MA27682A1 (fr) 2006-01-02
ECSP045029A (es) 2004-04-28
BR0212861A (pt) 2004-10-05
PL369297A1 (en) 2005-04-18
CA2461044A1 (en) 2003-04-03
US20030181501A1 (en) 2003-09-25
CA2461630A1 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
AP2004002999A0 (en) Organoleptically acceptable intraorally disintegrating compositions
MXPA03007613A (es) Composiciones y metodos de fabricacion para formas de dosis oral disolubles.
MXPA03010549A (es) Formas de dosificacion de oxcarbazepina.
TWI265808B (en) Valdecoxib compositions
AP1637A (en) Celecoxib compositions.
WO2004054974A3 (en) Piperidine derivatives as ccr5 antagonists
AU2003296992A1 (en) Pyrrolidine and azetidine compounds as ccr5 antagonists
MY130727A (en) Controlled-release pharmaceutical formulations
AU2003296993A8 (en) Cyclopropyl compounds as ccr5 antagonists
HUP0002316A2 (hu) Gyorsan olvadó orális adagolási formák
HRP20041158B1 (en) Orally disintegrating tablets and process for obtaining them
AU2003297048A1 (en) Cyclohexyl compounds as ccr5 antagonists
AU2002255321A1 (en) Tablets quickly disintegrating in the oral cavity and process for producing the same
ZA200501084B (en) Dispersible tablets for oral administration
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
IL158738A0 (en) Novel use of 2-phenyl-substituted imidazotriazinones
HK1054202B (zh) 口腔內崩解型固體製劑及其製備方法
EP1303300A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS
HK1061647A1 (en) Pharmaceutical compositions of rapmycins
YU37104A (sh) Preparati valdekoksiba sa oralnim razlaganjem dobijeni postupkom sušenja raspršivanjem
MXPA04004290A (es) Composiciones de valdecoxib que se disgregan intraoralmente preparadas mediante un procedimiento de granulacion en lecho fluido.
MXPA01009032A (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso se la produccion de il-12.
DE60212130D1 (en) Carvedilolpolymorph
MD2228F1 (en) Use of isothiouronic derivatives in the treatment and prophylaxis of intestinal atony
MD1938B1 (ro) Remediu pentru tratamentul afectiunilor parodontiului si mucoasei cavitatii bucale